CJC-1295 + Ipamorelin Blend: Dubai Research Vial COA & Purity
CJC-1295 + Ipamorelin — often searched together as CJC 1295 Ipamorelin — pairs a long-acting GHRH analog with a selective ghrelin-mimetic in a single blend vial, which makes the two-pathway identity easy to misread. The sections below cover identity, COA verification, and where the evidence stops — research-use framing throughout.
Update History ▾
June 8, 2026: Initial publication, drawing on the CJC-1295 + Ipamorelin component guides and peer-reviewed and official sources.
Research-use-only framing applied throughout in line with Remy editorial standards.
CJC-1295 + Ipamorelin is a two-pathway GH-axis research blend whose component studies are established, while the finished co-formulated blend is less directly studied. The format discussed in the literature is a fixed-ratio lyophilized blend. The sections below cover compound identity, the documentation a batch-specific COA should contain, and where the evidence stops. Remy Peptides has not published a batch record for this blend, so no first-party purity claim is made here.
Verifying the CJC-1295 + Ipamorelin blend
The blend is written several ways: cjc 1295 ipamorelin, cjc-1295 ipamorelin, and CJC-1295 + Ipamorelin blend. CJC-1295 is a GHRH analog also seen as mod GRF 1-29, while ipamorelin is a selective GHRP, or ghrelin-mimetic. The sections below separate identity documentation from the published evidence and treat reconstitution arithmetic as a laboratory-handling topic, not a dosing instruction.
For the deeper mechanism review, see the CJC-1295 + Ipamorelin blend guide; for the head-to-head pathway split, see CJC-1295 vs Ipamorelin.
Blend Identity: Two Complementary GH-Axis Pathways
The defining fact about this vial is that it is not one molecule. It locks two distinct research compounds together at reconstitution, each engaging a different arm of growth-hormone regulation:
- CJC-1295 is a long-acting analog of growth-hormone-releasing hormone (GHRH). Jette et al. identified it as a long-lasting hGRF(1-29) analog designed to bind serum albumin and prolong signaling duration in circulation.[1]
- Ipamorelin is a selective growth-hormone secretagogue that acts through the ghrelin / GHS-receptor pathway. Raun et al. described it as the first selective GH secretagogue, with potent GH-releasing activity and relative selectivity for the somatotropic axis in preclinical systems.[3]
Conceptually the blend is easy to read: one component extends GHRH-type signaling, and the other engages ghrelin-family GH-release signaling. That is the GHRH analog plus GHRP / ghrelin-mimetic pairing researchers describe when they pick this format. Critically, that conceptual clarity does not, by itself, create a direct evidence base for the finished commercial blend — a point the evidence map below keeps visible. For the full pathway-by-pathway split, the CJC-1295 vs Ipamorelin comparison separates the two timing and receptor profiles in detail.
Evidence Map and Translation Limits
A serious review has to separate component evidence, physiology rationale, and direct blend evidence. Those are not interchangeable categories. The component record is genuinely substantial: in healthy adults, Teichman et al. reported that a single CJC-1295 administration produced dose-dependent increases in mean plasma GH and IGF-1 over several days, with an estimated half-life of roughly 5.8 to 8.1 days.[2] Ipamorelin looks very different in practice: Gobburu et al. reported a short terminal half-life of about 2 hours and a single GH-release episode in healthy volunteers.[4] That contrast in timing is exactly why the two are paired rather than duplicated.
| Research layer | What the literature supports | What it means for interpretation |
|---|---|---|
| CJC-1295 component | Albumin-binding GHRH analog with prolonged GH/IGF-1 stimulation in healthy-adult research.[1][2] | Documentation should name the GHRH-side identity precisely — treat it as identity, not an outcome promise. |
| Ipamorelin component | Selective GH secretagogue with a short, single-pulse human PK/PD profile.[3][4] | Explains the ghrelin-side identity and why its timing differs from CJC-1295 — not a basis for any outcome claim. |
| Direct blend evidence | The cited set does not provide a mature peer-reviewed human trial of the marketed combined blend. | Treat the finished blend as component-backed, not trial-backed; do not read it as an approved therapeutic package. |
| Analytical documentation | A batch-specific record should state the format, lot number, identity method and quantitative purity result for each component. | Confirm that the issuing laboratory record matches the compound names and lot shown on the certificate. |
The right scientific sentence is that the blend is rationalized by component studies and physiology, but the blend itself is less directly studied than many casual summaries imply. That gap is not a reason to ignore the format — it is a reason to discuss it honestly and to lean on transparent COA and purity verification.
COA and Purity Verification
Because the co-formulated blend is component-backed rather than trial-backed, analytical verification carries more weight here than in single-molecule categories. For any blend vial, a batch-specific Certificate of Analysis should name and quantify each component separately — CJC-1295 and ipamorelin — so a lab can match compound identity to the lot before reconstitution.
Before comparing any CJC-1295 + Ipamorelin source (often searched as a cjc-1295 ipamorelin blend), confirm:
- The documentation states the 5mg + 5mg format, the lot number, and a quantitative purity figure per component.
- The page states Research Use Only and avoids human-use, veterinary-use, diagnostic, therapeutic, or disease-management claims.
- The certificate reports a quantitative result and an identity method, with each peptide listed separately.
- The certificate can be matched to a record held by the analysing laboratory.
The COA library demonstrates how batch records can be checked against the analysing laboratory. Its published records cover retatrutide batches only; it does not establish a purity result for CJC-1295 + Ipamorelin.
Blend Vial Format Reference
The table below records the stable format facts for the co-formulated blend vial and where each is documented.
| Field | Documented value |
|---|---|
| Blend reference | CJC-1295 + Ipamorelin blend guide |
| Format | 5mg + 5mg · Lyophilized research vial (10mg total combined peptide) |
| Ratio | Fixed 1:1 by mass; set at co-lyophilization, not adjustable lab-side |
| Combination evidence | Component studies established; the finished blend is not directly studied |
| COA context | The COA library shows the verification method on retatrutide records; no CJC-1295 + Ipamorelin batch record is published there. |
| Use restriction | For in-vitro laboratory research only. Not for human or veterinary use. |
For practical handling, the blend is a single lyophilized vial that pairs the GHRH analog and the ghrelin-receptor agonist from one reconstitution. The blend guide notes a worked example: a 5 mg + 5 mg vial reconstituted with 2 mL of bacteriostatic water yields roughly 2.5 mg/mL of each component. What casual searches call cjc-1295 ipamorelin dosage is, in a research context, this reconstitution-and-concentration math only — a calculator and handling topic, not a dosing instruction. See the blend guide for the research-use reconstitution context.
What This Page Does Not Claim
The research record helps define the compounds, but it does not turn an RUO blend vial into a clinical product. Keep these boundaries in view:
- Avoid muscle-gain, fat-loss, anti-aging, or recovery-result promises for the blend.
- Do not provide human-use instructions, protocols, or dosing.
- Do not imply the marketed blend carries the same evidence package as an approved GH-axis medicine.
Our Research Standards
This guide draws on the CJC-1295 + Ipamorelin component guides and peer-reviewed sources for each compound. It separates component evidence from blend claims on purpose, and makes no therapeutic, human-use, veterinary-use or first-party analytical claim. Read our editorial policy →
CJC-1295 + Ipamorelin Research FAQ
What documentation should a CJC-1295 + Ipamorelin blend vial carry?
A blend vial should carry a batch-specific Certificate of Analysis verifying each component separately — identity and HPLC purity for CJC-1295 and for Ipamorelin — plus confirmation of the 5mg + 5mg fill. The blend guide covers the pairing rationale; the COA library shows how a complete batch record reads.
What format does the CJC-1295 + Ipamorelin blend come in?
It is a single 5mg + 5mg lyophilized research vial holding 10mg total combined peptide at a fixed 1:1 mass ratio. Because the ratio is set at co-lyophilization, it cannot be varied lab-side — that is the structural trade-off against two separate vials.
How should researchers verify COA and purity for this blend vial?
Confirm that a batch-specific certificate names and quantifies CJC-1295 and ipamorelin separately, states the identity method and lot number, and can be matched to the analysing laboratory's record. Remy Peptides has not published a batch record for this blend; its COA library covers retatrutide batches only.
Is the commercial CJC-1295 + Ipamorelin blend as well studied as the individual components?
No. The published literature directly supports CJC-1295 and ipamorelin as separate components, and supports GHRH-family plus ghrelin-family synergy at the pathway level, but it is not the same as a mature direct human trial program for the marketed blend. This page is an evidence map, not a clinical-use guide.
Is the CJC-1295 + Ipamorelin blend intended for human or veterinary use?
No. This material is referenced strictly for in-vitro laboratory research. They are not for human use, veterinary use, diagnosis, treatment, cure, disease management, or personal-use protocols.
Sources
- Jette L, Leger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. doi: 10.1210/en.2004-1286 ↑
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. doi: 10.1210/jc.2005-1536 ↑
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PubMed: 9849822 ↑
- Gobburu JVS, Agerso H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416. doi: 10.1023/A:1018955126402 ↑
For the pairing rationale and component evidence, continue to the CJC-1295 + Ipamorelin blend guide and the CJC-1295 vs Ipamorelin comparison.